• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Cencora Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

    2/11/26 5:00:08 PM ET
    $COR
    Other Pharmaceuticals
    Health Care
    Get the next $COR alert in real time by email
    false 0001140859 0001140859 2026-02-10 2026-02-10 0001140859 us-gaap:CommonStockMember 2026-02-10 2026-02-10 0001140859 COR:Sec2.875SeniorNotesDue2028Member 2026-02-10 2026-02-10 0001140859 COR:Sec3.625SeniorNotesDue2032Member 2026-02-10 2026-02-10 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, DC 20549

     

     

     

    FORM 8-K

     

     

     

    CURRENT REPORT

    Pursuant to Section 13 or 15(d)
    of the Securities Exchange Act of 1934

     

    Date of Report (Date of earliest event reported): February 10, 2026

     

     

     

    Cencora, Inc.

    (Exact name of registrant as specified in its charter)

     

     

     

    Commission File Number: 1-16671

     

    Delaware   23-3079390
    (State or other jurisdiction of   (I.R.S. Employer
    incorporation or organization)   Identification No.)

     

    1 West First Avenue Conshohocken PA   19428-1800
    (Address of principal executive offices)   (Zip Code)

     

    (610) 727-7000

    (Registrant’s telephone number, including area code)

     

    Not Applicable

    (Former name or former address, if changed since last report.)

     

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class Trading Symbol(s) Name of exchange on which registered
    Common stock COR New York Stock Exchange (NYSE)
    2.875% Senior Notes due 2028 COR28 New York Stock Exchange (NYSE)
    3.625% Senior Notes due 2032 COR32 New York Stock Exchange (NYSE)

     

     

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     

    ¨Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

     

    ¨Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

     

    ¨Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

     

    ¨Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

     

    Emerging growth company ¨

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

     

     

     

     

     

     

    Item 7.01. Regulation FD Disclosure.

     

    On February 10, 2026, Cencora, Inc. (the “Company” or “Cencora”) issued a news release announcing that it priced $500,000,000 aggregate principal amount of the Company’s 3.950% Senior Notes due 2029 (the “2029 Notes”), $500,000,000 aggregate principal amount of the Company’s 4.250% Senior Notes due 2030 (the “2030 Notes”), $500,000,000 aggregate principal amount of the Company’s 4.600% Senior Notes due 2033 (the “2033 Notes”), $1,000,000,000 aggregate principal amount of the Company’s 4.900% Senior Notes due 2036 (the “2036 Notes”) and $500,000,000 aggregate principal amount of the Company’s 5.650% Senior Notes due 2056 (the “2056 Notes” and, together with the 2029 Notes, the 2030 Notes, the 2033 Notes and the 2036 Notes, the “Notes”) in an underwritten registered public offering. The news release is being furnished with this Current Report as Exhibit 99.1 and is incorporated herein by reference.

     

    Item 8.01. Other Events.

     

    On February 10, 2026, the Company entered into an Underwriting Agreement (the “Underwriting Agreement”), by and among the Company, Citigroup Global Markets Inc., J.P. Morgan Securities LLC, BofA Securities, Inc. and Wells Fargo Securities, LLC on behalf of themselves and as representatives of the several underwriters named therein (the “Underwriters”). The Underwriting Agreement provides for the issuance and sale by the Company, and the purchase by the Underwriters, of the Notes. The Notes will be senior unsecured obligations of the Company. The Underwriting Agreement contains representations, warranties, conditions and covenants of the parties thereto as well as provides for indemnification by each of the Company and the Underwriters against certain liabilities and contribution provisions in respect of those liabilities. Subject to the closing conditions specified in the Underwriting Agreement, the Company expects to consummate the sale of the Notes to the Underwriters on February 13, 2026.

     

    The offer and sale of the Notes have been registered under the Securities Act of 1933, as amended, pursuant to the Company’s shelf registration statement on Form S-3 (Registration Statement No. 333-283481) (the “Shelf Registration Statement”), filed with the Securities and Exchange Commission on November 26, 2024.

     

    If the sale of the Notes is consummated pursuant to the terms set forth in the Underwriting Agreement, the Company estimates that it will receive net proceeds of approximately $2.98 billion (after deducting the underwriting discount and offering expenses) from the sale of the Notes. The Company intends to use the net proceeds of the offering to repay amounts outstanding under the 364-Day Term Credit Agreement, dated as of January 12, 2026, by and among the Company, the lenders party thereto, and Citibank, N.A., as administrative agent, pursuant to which the Company obtained a $3.0 billion senior unsecured term loan facility (the “364-Day Term Loan Facility”), and, to the extent any proceeds remain, for general corporate purposes.

     

     

     

     

    Certain of the underwriters and their affiliates have in the past provided, and may in the future provide, investment banking, commercial banking, derivative transactions and financial advisory services to the Company and its affiliates in the ordinary course of business for which they have received and may continue to receive customary fees and commissions. Specifically, Citigroup Global Markets Inc., J.P. Morgan Securities LLC, BofA Securities, Inc. and Wells Fargo Securities, LLC or their affiliates and certain other underwriters have served as underwriters in connection with past senior note offerings by the Company and may serve similar roles in future securities offerings by the Company. Additionally, the underwriters or their affiliates also serve various roles in the Company’s multi-currency revolving credit facility dated as of June 4, 2025, as amended: JPMorgan Chase Bank, N.A., an affiliate of J.P. Morgan Securities LLC, serves as administrative agent, JPMorgan Chase Bank, N.A., BofA Securities, Inc., Citibank, N.A., an affiliate of Citigroup Global Markets Inc., Wells Fargo Securities, LLC, BNP Paribas Securities Corp. and Societe Generale, an affiliate of SG Americas Securities, LLC, serve as joint lead arrangers and joint bookrunners; Bank of America, N.A., an affiliate of BofA Securities, Inc., Citibank, N.A., Wells Fargo Bank, National Association, an affiliate of Wells Fargo Securities, LLC, BNP Paribas, an affiliate of BNP Paribas Securities Corp., and Societe Generale serve as syndication agents; Toronto-Dominion Bank, New York Branch, an affiliate of TD Securities (USA) LLC, serves as documentation agent; and Truist Bank, an affiliate of Truist Securities, Inc., serves as a lender. As of December 31, 2025, there were $220.0 million of borrowings outstanding under the Company’s commercial paper program, which is fully backed by the Company’s multi-currency revolving credit facility. The underwriters or their affiliates also serve various roles in the Company’s commercial paper program: Wells Fargo Securities, LLC serves as a dealer. Wells Fargo Bank, National Association is an uncommitted purchaser and a purchasing agent and related committed purchaser under the Company’s receivables securitization facility. As of December 31, 2025, the Company’s subsidiary, Amerisource Receivables Financial Corporation, had no borrowings outstanding under the receivables securitization facility. Additionally, certain of the underwriters or their affiliates also serve as lenders, agents and in other capacities under the Company’s credit facilities. Certain of the underwriters or their affiliates serve as lenders, agents and in other capacities under the Company’s Term Loan Facility dated as of November 26, 2024: Bank of America, N.A. serves as administrative agent, BofA Securities, Inc., Citibank, N.A., JPMorgan Chase Bank, N.A. and Wells Fargo Securities, LLC serve as joint lead arrangers and joint bookrunners; Citibank, N.A., JPMorgan Chase Bank, N.A. and Wells Fargo Bank, National Association serve as syndication agents; and BNP Paribas, Scotia Financing (USA) LLC, an affiliate of Scotia Capital (USA) Inc., Toronto-Domininon Bank, New York Branch, and Truist Bank serve as lenders. Certain of the underwriters or their affiliates serve as lenders, agents and in other capacities under the 364-Day Term Loan Facility, dated as of January 12, 2026: Citibank, N.A. serves as administrative agent and as a lender, Bank of America, N.A., JPMorgan Chase Bank, N.A, Wells Fargo Bank, National Association, BNP Paribas, The Bank of Nova Scotia, an affiliate of Scotia Capital (USA) Inc., Toronto-Dominion Bank, New York Branch, Truist Bank and First National Bank of Pennsylvania, an affiliate of FNB America Securities LLC, serve as lenders. Certain of the underwriters or their affiliates serve as lenders, agents and in other capacities under the Term Credit Agreement, dated as of January 12, 2026: JPMorgan Chase Bank, N.A. serves as administrative agent and as a lender, Citibank, N.A., Bank of America, N.A., Wells Fargo Bank, National Association serve as lenders BNP Paribas, Scotia Financing (USA) LLC, Toronto-Dominion Bank, New York Branch, and Truist Bank. Citigroup Global Markets Inc. served as lead financial advisor to the Company in connection with the acquisition of OneOncology, and J.P. Morgan Securities LLC also served as financial advisor. In addition, U.S. Bancorp Investments, Inc., one of the underwriters, is an affiliate of the trustee under the indentures governing the Notes.

     

     

     

     

    The foregoing is a brief description of certain terms of the Underwriting Agreement and, by its nature, is incomplete. It is qualified in its entirety by the text of the Underwriting Agreement filed as Exhibit 1.1 to this Current Report and incorporated herein by reference. The Underwriting Agreement is also filed with reference to, and is hereby made an exhibit to, the Shelf Registration Statement.

     

    Forward-Looking Statements

     

    Certain of the statements contained in this Current Report on Form 8-K are “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the “Securities Exchange Act”). Words such as “aim,” “anticipate,” “believe,” “can,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “on track,” “opportunity,” “plan,” “possible,” “potential,” “predict,” “project,” “seek,” “should,” “strive,” “sustain,” “synergy,” “target,” “will,” “would” and similar expressions are intended to identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. These statements are based on management’s current expectations and are subject to uncertainty and changes in circumstances and speak only as of the date hereof. These statements are not guarantees of future performance and are based on assumptions and estimates that could prove incorrect or could cause actual results to vary materially from those indicated. A more detailed discussion of the risks and uncertainties that could cause the Company’s actual results to differ materially from those indicated is included in the “Risk Factors” and “Management’s Discussion and Analysis” sections in the Company’s Annual Report on Form 10-K for the fiscal year ended September 30, 2025 and elsewhere in that report and other reports filed by the Company pursuant to the Securities Exchange Act. The Company undertakes no obligation to publicly update or revise any forward-looking statements, except as required by the federal securities laws.

     

    Item 9.01. Financial Statements and Exhibits. 

     

    (d)Exhibits.

     

    Exhibit
    Number
      Description  
       
    1.1   Underwriting Agreement, dated as of February 10, 2026, by and among Cencora, Inc., Citigroup Global Markets Inc., J.P. Morgan Securities LLC, BofA Securities, Inc. and Wells Fargo Securities, LLC, as representatives of the underwriters listed in Schedule 1 thereto.
    99.1   News release of Cencora, Inc., dated February 10, 2026.
    104   Cover Page Interactive Data File (formatted as Inline XBRL)

     

     

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

      Cencora, Inc.
           
    February 11, 2026 By: /s/ James F. Cleary
        Name: James F. Cleary
        Title: Executive Vice President and Chief Financial Officer

     

     

     

    Get the next $COR alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $COR

    DatePrice TargetRatingAnalyst
    1/29/2026$400.00Equal-Weight → Overweight
    Morgan Stanley
    1/22/2026$440.00Hold → Buy
    Jefferies
    12/9/2025$400.00Overweight
    Barclays
    6/3/2025$337.00Equal Weight → Overweight
    Wells Fargo
    12/4/2024$280.00Outperform
    Mizuho
    9/18/2024$275.00 → $245.00Buy → Neutral
    BofA Securities
    2/26/2024$261.00Outperform
    Leerink Partners
    1/3/2024$242.00Overweight
    Barclays
    More analyst ratings

    $COR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 3 filed by new insider Cooper Ellen

    3 - Cencora, Inc. (0001140859) (Issuer)

    1/30/26 3:59:47 PM ET
    $COR
    Other Pharmaceuticals
    Health Care

    President & CEO Mauch Robert P. exercised 3,763 shares at a strike of $86.09 and sold $1,807,704 worth of shares (5,096 units at $354.73), decreasing direct ownership by 2% to 66,726 units (SEC Form 4)

    4 - Cencora, Inc. (0001140859) (Issuer)

    1/22/26 4:43:25 PM ET
    $COR
    Other Pharmaceuticals
    Health Care

    Clyburn Frank increased direct ownership by 0.35% to 1,161 units (SEC Form 5)

    5 - Cencora, Inc. (0001140859) (Issuer)

    1/16/26 4:12:52 PM ET
    $COR
    Other Pharmaceuticals
    Health Care

    $COR
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Cencora Prices $500 Million 3.950% Senior Notes Due 2029, $500 Million 4.250% Senior Notes Due 2030, $500 Million 4.600% Senior Notes Due 2033, $1.0 Billion 4.900% Senior Notes Due 2036 and $500 Million 5.650% Senior Notes Due 2056

    Cencora, Inc. (NYSE:COR) today announced that it priced $500 million aggregate principal amount of its 3.950% Senior Notes due February 13, 2029 (the "2029 Notes"), $500 million aggregate principal amount of its 4.250% Senior Notes due November 15, 2030 (the "2030 Notes"), $500 million aggregate principal amount of its 4.600% Senior Notes due February 13, 2033 (the "2033 Notes"), $1.0 billion aggregate principal amount of its 4.900% Senior Notes due February 13, 2036 (the "2036 Notes") and $500 million aggregate principal amount of its 5.650% Senior Notes due February 13, 2056 (the "2056 Notes" and, together with the 2029 Notes, the 2030 Notes, the 2033 Notes and the 2036 Notes, the "Notes"

    2/10/26 5:15:00 PM ET
    $COR
    Other Pharmaceuticals
    Health Care

    Cencora Reports Fiscal 2026 First Quarter Results

    Revenue of $85.9 billion for the First Quarter, a 5.5% Increase Year-Over-Year First Quarter GAAP Diluted EPS of $2.87 and Adjusted Diluted EPS of $4.08 Adjusted Operating Income Guidance Raised to Growth of 11.5% to 13.5% Adjusted Diluted EPS Guidance Range Reaffirmed at $17.45 to $17.75 for Fiscal 2026 Company Completes Acquisition of OneOncology Cencora, Inc. (NYSE:COR) reported that in its fiscal year 2026 first quarter ended December 31, 2025, revenue increased 5.5 percent year-over-year to $85.9 billion. On the basis of U.S. generally accepted accounting principles (GAAP), diluted earnings per share (EPS) was $2.87 for the first quarter of fiscal 2026 compared to $2.50 in th

    2/4/26 6:30:00 AM ET
    $COR
    Other Pharmaceuticals
    Health Care

    Cencora Elects Ellen Cooper to Its Board of Directors

    Cencora, Inc. (NYSE:COR) today announced that its Board of Directors has elected Ellen Cooper as a new independent director, effective January 20, 2026. Ms. Cooper is the Chairman, President and Chief Executive Officer of Lincoln Financial. Prior to assuming the role of CEO in May 2022, she served as Executive Vice President, Chief Investment Officer, Head of Enterprise Risk and Annuity Solutions. Prior to joining Lincoln, Ms. Cooper was with Goldman Sachs Asset Management, where she served as Managing Director and Global Head of Insurance Strategy. Earlier in her career, she was the Chief Risk Officer for AEGON Americas and a Principal at Ernst & Young LLP. "Ellen's expertise in risk m

    1/22/26 7:30:00 AM ET
    $COR
    Other Pharmaceuticals
    Health Care

    $COR
    SEC Filings

    View All

    Cencora Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

    8-K - Cencora, Inc. (0001140859) (Filer)

    2/11/26 5:00:08 PM ET
    $COR
    Other Pharmaceuticals
    Health Care

    SEC Form FWP filed by Cencora Inc.

    FWP - Cencora, Inc. (0001140859) (Subject)

    2/10/26 5:26:44 PM ET
    $COR
    Other Pharmaceuticals
    Health Care

    SEC Form 424B5 filed by Cencora Inc.

    424B5 - Cencora, Inc. (0001140859) (Filer)

    2/10/26 9:53:46 AM ET
    $COR
    Other Pharmaceuticals
    Health Care

    $COR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Cencora upgraded by Morgan Stanley with a new price target

    Morgan Stanley upgraded Cencora from Equal-Weight to Overweight and set a new price target of $400.00

    1/29/26 6:57:57 AM ET
    $COR
    Other Pharmaceuticals
    Health Care

    Cencora upgraded by Jefferies with a new price target

    Jefferies upgraded Cencora from Hold to Buy and set a new price target of $440.00

    1/22/26 8:20:03 AM ET
    $COR
    Other Pharmaceuticals
    Health Care

    Barclays initiated coverage on Cencora with a new price target

    Barclays initiated coverage of Cencora with a rating of Overweight and set a new price target of $400.00

    12/9/25 8:43:35 AM ET
    $COR
    Other Pharmaceuticals
    Health Care

    $COR
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Durcan Dermot Mark bought $109,290 worth of shares (500 units at $218.58), increasing direct ownership by 2% to 21,876 units (SEC Form 4)

    4 - Cencora, Inc. (0001140859) (Issuer)

    5/29/24 4:02:27 PM ET
    $COR
    Other Pharmaceuticals
    Health Care

    $COR
    Leadership Updates

    Live Leadership Updates

    View All

    Cencora Appoints Mark Durcan as Chairman of Its Board of Directors

    Cencora, Inc. (NYSE:COR) today announced that its Board of Directors has appointed Lead Independent Director D. Mark Durcan as Chairman of the Board of Directors, effective October 1, 2025. Mr. Durcan will succeed Steven H. Collis, who has served as Cencora's Chairman since 2016 and previously served as Cencora's Chief Executive Officer from 2011 until 2024. As previously disclosed, Mr. Collis was elected to serve as Executive Chairman of the Board effective October 1, 2024 for a period of one year. "Our Board is confident that Mark's public company CEO and board experience, along with his strategic planning and technological innovation experience, make him the right person to step into t

    8/27/25 4:15:00 PM ET
    $COR
    Other Pharmaceuticals
    Health Care

    Cencora Expands Enterprise Leadership Team with Two Senior Appointments

    Francois Mandeville Named Executive Vice President, Strategy and M&A Pawan Verma Appointed Executive Vice President, Chief Data and Information Officer Cencora, Inc. (NYSE:COR) today announced the appointment of Francois Mandeville as Executive Vice President, Strategy and M&A, and Pawan Verma as Executive Vice President, Chief Data and Information Officer. Both leaders will join Cencora's enterprise leadership team, bringing their extensive experience and expertise to help advance the company's pharmaceutical-centric strategy and drive growth for Cencora and its customers. "We're thrilled to welcome Francois and Pawan to Cencora's leadership team," said Bob Mauch, President and Chief Ex

    11/4/24 8:30:00 AM ET
    $COR
    Other Pharmaceuticals
    Health Care

    Network Wireless Solutions (NWS) Appoints Michael Millegan to Board of Directors

    The communications industry veteran brings years of experience to NWS Network Wireless Solutions, LLC ("NWS"), a rapidly growing solutions and logistics provider to carriers and telecommunications contractors, announced today the appointment of Michael Millegan to its board. NWS is a portfolio company of Grain Management, LLC ("Grain"), a leading Washington, D.C.-based investment firm focused on the global communications sector. Mr. Millegan is a seasoned technology executive with several years of experience leading company strategy, including sales, marketing, supply chain operations, cell site build-out, and engineering. Currently, Mr. Millegan serves as an independent board director fo

    9/14/21 2:00:00 PM ET
    $AXS
    $COR
    $POR
    Property-Casualty Insurers
    Finance
    Other Pharmaceuticals
    Health Care

    $COR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Cencora Inc.

    SC 13G/A - Cencora, Inc. (0001140859) (Subject)

    11/14/24 1:22:34 PM ET
    $COR
    Other Pharmaceuticals
    Health Care

    Amendment: SEC Form SC 13D/A filed by Cencora Inc.

    SC 13D/A - Cencora, Inc. (0001140859) (Subject)

    8/5/24 6:43:49 PM ET
    $COR
    Other Pharmaceuticals
    Health Care

    SEC Form SC 13G/A filed by CoreSite Realty Corporation (Amendment)

    SC 13G/A - CoreSite Realty Corp (0001490892) (Subject)

    7/12/21 8:29:18 AM ET
    $COR
    Other Pharmaceuticals
    Health Care

    $COR
    Financials

    Live finance-specific insights

    View All

    Cencora Reports Fiscal 2026 First Quarter Results

    Revenue of $85.9 billion for the First Quarter, a 5.5% Increase Year-Over-Year First Quarter GAAP Diluted EPS of $2.87 and Adjusted Diluted EPS of $4.08 Adjusted Operating Income Guidance Raised to Growth of 11.5% to 13.5% Adjusted Diluted EPS Guidance Range Reaffirmed at $17.45 to $17.75 for Fiscal 2026 Company Completes Acquisition of OneOncology Cencora, Inc. (NYSE:COR) reported that in its fiscal year 2026 first quarter ended December 31, 2025, revenue increased 5.5 percent year-over-year to $85.9 billion. On the basis of U.S. generally accepted accounting principles (GAAP), diluted earnings per share (EPS) was $2.87 for the first quarter of fiscal 2026 compared to $2.50 in th

    2/4/26 6:30:00 AM ET
    $COR
    Other Pharmaceuticals
    Health Care

    Cencora Announces Date and Time for First Quarter Fiscal 2026 Earnings Release

    Cencora, Inc. (NYSE:COR) today announced that it plans to release its results for the First Quarter of Fiscal 2026 on Wednesday, February 4, 2026, prior to the opening of trading on the New York Stock Exchange. The Company will host a conference call to discuss the results at 8:30 a.m. ET on February 4, 2026. Participating in the conference call will be: Robert P. Mauch, President & Chief Executive Officer James F. Cleary, Executive Vice President & Chief Financial Officer The live call will be webcast via the Company's website at investor.cencora.com. Users are encouraged to log on to the webcast approximately 10 minutes in advance of the scheduled start time of the call. To access t

    1/6/26 4:30:00 PM ET
    $COR
    Other Pharmaceuticals
    Health Care

    Cencora Reports Fiscal 2025 Fourth Quarter and Fiscal Year End Results

    Revenue of $83.7 Billion for the Fourth Quarter, a 5.9 Percent Year-Over-Year Increase Fourth Quarter GAAP Diluted EPS of $(1.75) and Adjusted Diluted EPS of $3.84 Revenue of $321.3 Billion for Fiscal Year 2025, a 9.3 Percent Year-Over-Year Increase Fiscal Year 2025 GAAP Diluted EPS of $7.96 and Adjusted Diluted EPS of $16.00 Company increases its quarterly dividend by 9 percent Company raises its long-term guidance expectations Cencora, Inc. (NYSE:COR) today reported that in its fiscal year 2025 fourth quarter ended September 30, 2025, revenue increased 5.9 percent to $83.7 billion. Revenue increased 9.3 percent to $321.3 billion for fiscal year 2025. On the basis of U.S. generally a

    11/5/25 6:30:00 AM ET
    $COR
    Other Pharmaceuticals
    Health Care